A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting

Leukemia, Lymphocytic, Chronic, B-Cell Clinical Trial

— EVIdeNCE  

Official title:

EValuate Ibrutinib Retention iN Chronic Lymphocytic Leukemia Patients Treated in a rEal World Setting - EVIdeNCE

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03720561
• Other study ID #: CR108517
• Secondary ID: 54179060CLL4013
• Status: Completed
• Start date: October 30, 2018
• Est. completion date: November 12, 2021

Study information

• Verified date: December 2021
• Source: Janssen-Cilag S.p.A.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to describe the 2-year retention rate of ibrutinib treatment for chronic lymphocytic leukemia (CLL) in Italian routine clinical practice.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 312
• Est. completion date: November 12, 2021
• Est. primary completion date: November 12, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Must have a confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) requiring treatment (iwCLL [International Workshop on Chronic Lymphocytic Leukemia] criteria)

• If alive, must sign an Informed Consent Form (ICF) allowing data collection and source data verification in accordance with Italian requirements

• Participants with one of the following characteristics: a) Participants starting ibrutinib treatment according to the summary of product characteristics (SmPC) at enrolment or within 30 days starting from informed consent signature, as per routine clinical practice and independently of this non-interventional study; OR b) Participants who have started ibrutinib within 3 months before enrollment, according to the SmPC, as per routine clinical practice and independently of this non- interventional study (including also participants who, by the time of enrollment, are not receiving ibrutinib)

• If alive, must be able to read and write in Italian and to understand and sign the ICF

Exclusion Criteria:

• Currently enrolled in any interventional clinical trial

• Currently enrolled in observational studies sponsored or managed by Janssen company

• Treated with any investigational compound or any invasive investigational medical device within 30 days before start of ibrutinib treatment

• Having contraindications to ibrutinib use as described in the SmPC

• Pregnant or breast-feeding

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid

Intervention

Drug:
• Ibrutinib
Participants in this observational study with confirmed diagnosis of CLL receiving ibrutinib in routine clinical practice settings will be observed approximately for 3 years.

Locations

Country	Name	City	State
Italy	Ospedali Riuniti Di Ancona	Ancona
Italy	U.O.C. Ematologia e Terapia Cellulare Ospedale C e G Mazzoni	Ascoli Piceno
Italy	U.O. Ematologia con Trapianto- AOU Policlinico di Bari	Bari
Italy	U.O. Ematologia Istituto Tumori Giovanni Paolo II	Bari
Italy	S.C. Ematologia e CTMO P.O. Businco A.O. Brotzu	Cagliari
Italy	AORN Sant'anna e San Sebastiano	Caserta
Italy	Div.Clinicizzata EmatologiaconTrapiantodi MidolloOsseo P.O.Rodoligo AOUPoliclinico-Vittorio Emanuele	Catania
Italy	S.O.C. Ematologia P.O. Ciaccio A.O. Pugliese-Ciaccio	Catanzaro
Italy	Azienda Ospedaliero Universitaria di Ferrara	Cona
Italy	S.C. Ematologia Azienda Ospedaliera S. Croce e Carle	Cuneo
Italy	Unità Funzionale di Ematologia Azienda ospedaliero-universitaria Careggi	Firenze
Italy	S.C. Ematologia A.O.U. Ospedali Riuniti	Foggia
Italy	Ematologia Ospedale San Martino	Genova
Italy	U.O.C. Ematologia Ospedale V. Fazzi	Lecce
Italy	Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori	Meldola
Italy	Divisione ematologia Grande Ospedale Metropolitano Niguarda	Milano
Italy	Programma di ricerca strategica sulla LLC Ospedale San Raffaele	Milano
Italy	U.O.C. Ematologia Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico	Milano
Italy	Division of Hematology, Cardarelli Hospital	Napoli
Italy	U.O.C. Ematologia e Trapianti di midollo A.O.U. Federico II	Napoli
Italy	Ospedale San Francesco	Nuoro
Italy	U.O.C. Ematologia e Immunologia Clinica Azienda Ospedaliera Padova	Padova
Italy	U.O. Ematologia ed Oncologia Ospedale A. Tortora	Pagani
Italy	Ospedale 'Villa Sofia-Cervello	Palermo
Italy	Fondazione IRCCS Policlinico San Matteo	Pavia
Italy	S.C. Ematologia A.O.U. Santa Maria della Misericordia	Perugia
Italy	UOSD Centro diagnosi e terapia dei linfomi Ospedale Santo Spirito	Pescara
Italy	U.O.C. Ematologia Ospedale S. Maria delle Croci	Ravenna
Italy	Arcispedale Santa Maria Nuova - IRCCS	Reggio Emilia
Italy	Azienda Ospedaliera Sant Andrea	Roma
Italy	DH Oncoematologia Policlinico Tor Vergata	Roma
Italy	Ematologia Fondazione Univ. Policlinico Gemelli Università Cattolica del Sacro Cuore	Roma
Italy	Università di Roma 'La Sapienza' - Ospedale Umberto 1°	Roma
Italy	UO Oncologia ed Ematologia Istituto Clinico Humanitas	Rozzano
Italy	U.O.C. Ematologia e Trapianti Cellule Staminali Emopoietiche AOU S.Giovanni di Dio e Ruggi D'Aragona	Salerno
Italy	Ospedale 'Casa Sollievo della Sofferenza' - U.O. Ematologia-	San Giovanni Rotondo
Italy	Azienda Ospedaliera 'Santa Maria'	Terni
Italy	S.C. Ematologia U A.O.U. Citta della Salute e della Scienza P.O.Molinette	Torino
Italy	U.O. Ematologia Ospedale San Bortolo	Vicenza

Sponsors (1)

Lead Sponsor	Collaborator
Janssen-Cilag S.p.A.

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Retention Rate of Ibrutinib	The retention rate is defined as the ratio of the number of participants taking ibrutinib over the number of participants at risk. The retention rate of ibrutinib treatment for (Chronic lymphocytic leukemia) CLL in Italian routine clinical practice will be measured.	Approximately up to 2 years
Secondary	Number of Participants Requiring Dose Modifications	Number of CLL participants with at least one ibrutinib treatment dose modification (that is, increase/decrease) will be reported.	Approximately up to 2 years
Secondary	Overall Response Rate (ORR)	The ORR will be calculated as the proportion of participants who achieve either complete response (CR), partial response (PR) or partial response with lymphocytosis, as assessed by the participating physician. The ORR in CLL participants as per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria is defined as normal circulating lymphocyte count during CR and decrease by greater than or equal to (>=) 50 percent (%) during PR.	Approximately up to 2 years
Secondary	Time to Best Response	Time to best response is defined as the time from start of ibrutinib therapy until best objective response. Best response will be evaluated based on the following generally accepted algorithm: complete response greater than (>) partial response > partial response with lymphocytosis > stable disease > progressive disease.	Approximately up to 2 years
Secondary	Time to Treatment Discontinuation(TTD)	Time to treatment discontinuation (TTD) will be calculated as the difference between ibrutinib initiation date and ibrutinib permanent discontinuation date.	Approximately up to 2 years
Secondary	Time to Next Therapy (TTNT)	The TTNT will be calculated as the difference between ibrutinib initiation date and initiation date of the first next therapy for CLL.	Approximately up to 2 years
Secondary	Progression Free Survival (PFS)	PFS is defined as the duration from date of ibrutinib initiation to date of disease progression (PD [according to the physician's evaluation]) or death from any cause. PD is defined as >= 50% increase in circulating lymphocyte count as per iwCLL criteria.	From the date of assignment until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 2 years
Secondary	Overall Survival (OS)	The OS in CLL participants will be measured and reported from start of ibrutinib therapy to the date of death (all-cause mortality); and from diagnosis to the date of death.	From the date of assignment until the date of death from any cause, whichever comes first, assessed up to 2 years
Secondary	Number of Participants with Clinically Significant Change in Hematologic Parameters	Number of participants with change in hematologic parameters (complete blood count, hemoglobin, leukocyte count, lymphocyte count, neutrophil count, platelet count) will be determined.	Approximately up to 2 years
Secondary	Number of Participants with Clinically Significant Change in Biochemistry Parameters	Number of participants with clinically significant change in biochemistry parameters (including lactate dehydrogenase [LDH] and creatinine clearance) will be determined.	Approximately up to 2 years
Secondary	Change from Baseline in Immunoglobulin levels	Changes in the immunoglobulin levels from baseline will be reported.	Baseline up to 2 years
Secondary	Number of Participants with at least one Clinical Significant Characteristics	Number of participants with at least one of the following conditions: lymphadenopathy, hepatosplenomegaly, bone marrow involvement, or B-symptoms as provided will be reported.	Approximately 2 years
Secondary	Number of Participants with Each Grade of Eastern Cooperative Oncology Group (ECOG) Performance Status Score	ECOG performance status is a standard criterion for measuring how the disease impacts daily living abilities. It describes the level of functioning in terms of the ability to care for oneself, daily activity, and physical ability (walking, working, etc). ECOG performance status score ranges from Grade 0 to 5: 0) Fully active and performances without restriction, 1) Restricted in physically strenuous activity, 2) Ambulatory and capable of all self-care but unable to carry out any work activities, 3) Capable of only limited self-care and confined to bed or chair more than 50% of waking hours, 4) Completely disabled, and 5) Dead.	Approximately up to 2 years
Secondary	Percentage of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs) and Special Situations	An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. An SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above. Percentage of participants with AEs, all serious AEs, and all special situations (for example, medication error, overdosing, abuse, lack of effect, unexpected benefits following exposure to ibrutinib) will be reported.	Approximately up to 2 years
Secondary	Health-Related Quality of Life as Measured by European Quality of Life-5 Dimensions; 5 Levels Questionnaire (EQ-5D-5L)	The EQ-5D questionnaire is a brief, generic health-related quality of life assessment (HRQOL) that can also be used to incorporate participant preferences into health economic evaluations. The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression and as overall health using a "thermometer" visual analog scale with response options ranging from 0 (worst imaginable health) to 100 (best imaginable health).	Approximately up to 2 years
Secondary	Health-Related Quality of Life as Measured by European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) Scores	EORTC QLQ-30 designed to measure cancer patients' physical, psychological and social functions. It is composed of multi-item scales (physical, role, social, emotional and cognitive functioning) and single items (pain, fatigue, financial impact, appetite loss, nausea/vomiting, diarrhea, constipation, sleep disturbance and quality of life); high scores on the global and functional scales but low scores on the symptom scales indicate good QOL. QLQ-C30 has four-point scales for the first five items. These are coded with the same response categories as items 6 to 28, namely "Not at all", "A little", "Quite a bit" and "Very much." For items 29 and 30, a seven-point scale (ranging from 1 = "Very Poor" to 7 = "Excellent") rates overall health and overall quality of life.	Approximately up to 2 years
Secondary	Medical Resource Utilization	Number of medical care encounters and treatments (including physician or emergency room visits, tests and procedures, and medications, surgeries and other procedures [such as computerized tomography {CT}, x-ray]) will be reported.	Approximately up to 2 years
Secondary	Duration of Hospitalization	Duration of hospitalization is defined as number of days from the day of admission to discharge (total days length of stay), including duration by wards (for example, intensive care unit).	Approximately up to 2 years
Secondary	Duration of Medical Care Encounters	Duration of medical care encounters, including surgeries, and other selected procedures (inpatient and outpatient) will be reported.	Approximately up to 2 years
Secondary	Number of Participants Requiring Blood and Platelets Transfusions	Number of participants requiring blood and platelets transfusions will be reported.	Approximately up to 2 years
Secondary	Number of Participants Requiring Erythropoietin and Growth Factor Administrations	Number of participants requiring erythropoietin and growth factor administrations will be reported.	Approximately up to 2 years